Elevated Treasury yields near 19-year highs and the Federal Reserve’s September 2026 rate increase to the 3.75–4.00% range have compressed growth valuations and prompted some postponements, yet the IPO pipeline remains active with multiple offerings scheduled through year-end. Small and mid-sized deals continue to price, including Iambic Therapeutics and City Therapeutics in mid-October, while larger candidates such as Anthropic target November listings at valuations exceeding $1.8 trillion. Equity market resilience, supported by AI-driven earnings and investor risk appetite, has enabled recent completions like TRex Bio despite aftermarket volatility. With dozens of filings already in process and historical patterns showing year-end acceleration, trader consensus heavily favors additional IPOs before 2027, though a sharp yield spike or weak debut could delay marginal candidates into early 2027.